Skip to main content

Nordic Nanovector ASA (NANOV.OL)

26.7Poor

ValueMarkers Composite Index

Top 0%#44,693 of 44,714

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Nordic Nanovector ASA (NANOV.OL) — VMCI valuation read

Composite valuation read on NANOV.OL: VMCI 27/100 against a broad-market sample median of 50. The 23-point below-median print is the headline number for Nordic Nanovector ASA, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for NANOV.OL: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on NANOV.OL: NANOV.OL trades at 25.0x earnings, 39% above the sector median of 18.0x; ROIC of 17.0% sits 7.0pp above the sector median (10.0%); net debt to EBITDA of -0.9x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for sector closes the value frame.

NANOV.OL rose 3.6% over the trailing 7 days, with a +3.4% read on a 30-day basis.

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

CEO: Ludvik Sandnes18 employeesNOwww.nordicnanovector.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in NANOV.OL’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.